The "Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022" report has been added to Research and Markets' offering. "Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook ...

LONDON, Nov. 13, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5193339 As per report findings, CDK inhibitors have emerged as new ...

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Breast Cancer - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report delivers in-depth insights into over 250 ...

CHICAGO — Raj Malik, MD, chief medical officer and senior vice president for research and development at G1 Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about study results the company ...

DUBLIN--(BUSINESS WIRE)--The "Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics - Pipeline Analysis 2017" report has been added to Research and Markets' offering. The study analyzed that the CDK ...

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation ...

Each year, two million individuals are diagnosed with breast cancer, resulting in over 685,000 deaths worldwide 1. Although breast cancer is the most commonly diagnosed cancer globally 2, each ...

Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Kailera Therapeutics launched with a four-drug pipeline aimed at the ...

(MENAFN- GlobeNewsWire - Nasdaq) The breast cancer pipeline presents significant opportunities with over 250 companies and 300+ drugs under development, including innovative approaches like PROTACs, ...